pharmaphorum January 10, 2022
Ben Hargreaves

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Ben Hargreaves takes a look at how the space is currently progressing and in what direction it could be heading in future.

The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individual treatments. Previously, messenger RNA (mRNA) therapies were a niche part of the global R&D pipeline, now a wide section of the public is at least familiar with the name of this type of therapy.

The first mRNA-based vaccines were brought onto the market...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article